Tokyo Tape
Sign in
← Trans Genic Group

Half-year report · Q2

2342.TEDINET S100UI5X
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥6.3bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥13.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥6.4bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income−¥111m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥89m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥157m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥108m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥95m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥195m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥94m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥182m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥48m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥185m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥42m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥10.6bnat 2024-09-30Cons.Assets
Total assets¥9.8bnat 2024-03-31Cons.Assets
Total assets¥10.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.8bnat 2024-09-30Cons.Liabilities
Total liabilities¥3.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥5.8bnat 2024-09-30Cons.Net assets
Net assets / equity¥6.0bnat 2024-03-31Cons.Net assets
Net assets / equity¥6.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.3bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥2.5bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥2.2bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.5bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥421m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥392m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥366m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥175m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥281m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥129m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥379m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥343m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥47m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-10.972024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.242023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥2.872023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio53.5%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio60.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥114m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥806m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥803m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥189m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥45,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥192m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥3m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥108m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥981m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥978m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥27m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥628,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥223m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥4m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥196m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Other clPrior1YearInstant231815000JPY
Other clCurrentQuarterInstant116104000JPY
Current liabilitiesPrior1YearInstant2434288000JPY
Current liabilitiesCurrentQuarterInstant3587181000JPY
Bonds payablePrior1YearInstant123000000JPY
Bonds payableCurrentQuarterInstant116000000JPY
Long term loans payablePrior1YearInstant1184570000JPY
Long term loans payableCurrentQuarterInstant1023878000JPY
Long term accounts payable otherPrior1YearInstant13526000JPY
Long term accounts payable otherCurrentQuarterInstant10108000JPY
Net defined benefit liabilityPrior1YearInstant37644000JPY
Net defined benefit liabilityCurrentQuarterInstant68633000JPY
Other nclPrior1YearInstant19506000JPY
Other nclCurrentQuarterInstant15558000JPY
Noncurrent liabilitiesPrior1YearInstant1378246000JPY
Noncurrent liabilitiesCurrentQuarterInstant1234178000JPY
LiabilitiesPrior1YearInstant3812535000JPY
LiabilitiesCurrentQuarterInstant4821359000JPY
Capital stockPrior1YearInstant50000000JPY
Capital stockCurrentQuarterInstant50000000JPY
Capital surplusPrior1YearInstant3861314000JPY
Capital surplusCurrentQuarterInstant3857377000JPY
Retained earningsPrior1YearInstant2067097000JPY
Retained earningsCurrentQuarterInstant1835056000JPY
Treasury stockPrior1YearInstant-135948000JPY
Treasury stockCurrentQuarterInstant-116016000JPY
Shareholders equityPrior1YearInstant5842463000JPY
Shareholders equityCurrentQuarterInstant5626417000JPY
Valuation difference on available for sale securitiesPrior1YearInstant25959000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant12110000JPY
Foreign currency translation adjustmentPrior1YearInstant25461000JPY
Foreign currency translation adjustmentCurrentQuarterInstant23662000JPY
Valuation and translation adjustmentsPrior1YearInstant51420000JPY
Valuation and translation adjustmentsCurrentQuarterInstant35773000JPY
Subscription rights to sharesPrior1YearInstant200000JPY
Subscription rights to sharesCurrentQuarterInstant200000JPY
Non controlling interestsPrior1YearInstant104380000JPY
Non controlling interestsCurrentQuarterInstant91593000JPY
Net assetsPrior1YearInstant5998464000JPY
Net assetsCurrentQuarterInstant5753984000JPY
Liabilities and net assetsPrior1YearInstant9810999000JPY
Liabilities and net assetsCurrentQuarterInstant10575344000JPY
Net salesPrior1YTDDuration6377299000JPY
Net salesCurrentYTDDuration6311881000JPY
Cost of salesPrior1YTDDuration5212219000JPY
Cost of salesCurrentYTDDuration5197343000JPY
Gross profitPrior1YTDDuration1165079000JPY
Gross profitCurrentYTDDuration1114537000JPY
Selling general and administrative expensesPrior1YTDDuration1076556000JPY
Selling general and administrative expensesCurrentYTDDuration1225307000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass